Aurobindo Pharma Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Aurobindo Pharma kazanç ve gelirin sırasıyla yıllık 13.9% ve 8.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 13.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 12.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

13.9%

Kazanç büyüme oranı

13.7%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.5%
Gelir büyüme oranı	8.4%
Gelecekteki özkaynak getirisi	12.8%
Analist kapsamı	Good
Son güncelleme	19 Dec 2024

Gelecekteki son büyüme güncellemeleri

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Nov 12

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29

Recent updates

Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?

Dec 18

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Nov 12

Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Oct 20

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Sep 10

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27

Kazanç ve Gelir Büyüme Tahminleri

NSEI:AUROPHARMA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	371,099	49,285	42,798	59,262	24
3/31/2026	348,000	45,822	35,327	53,506	28
3/31/2025	314,859	37,231	30,832	45,923	28
9/30/2024	302,950	35,816	-7,760	15,867	N/A
6/30/2024	297,184	35,214	N/A	N/A	N/A
3/31/2024	290,019	31,730	-11,270	24,345	N/A
12/31/2023	278,947	27,705	N/A	N/A	N/A
9/30/2023	269,500	23,254	-16,080	19,946	N/A
6/30/2023	254,700	19,777	N/A	N/A	N/A
3/31/2023	248,554	19,275	-3,336	23,868	N/A
12/31/2022	241,918	19,977	N/A	N/A	N/A
9/30/2022	237,869	21,112	28,497	52,208	N/A
6/30/2022	239,894	23,987	N/A	N/A	N/A
3/31/2022	234,555	26,482	23,118	50,165	N/A
12/31/2021	236,476	28,676	N/A	N/A	N/A
9/30/2021	240,103	52,109	1,278	28,769	N/A
6/30/2021	245,518	53,217	N/A	N/A	N/A
3/31/2021	247,746	53,348	14,552	33,291	N/A
12/31/2020	249,316	53,831	N/A	N/A	N/A
9/30/2020	244,617	31,421	29,266	42,542	N/A
6/30/2020	235,787	29,757	N/A	N/A	N/A
3/31/2020	230,985	28,451	29,502	43,813	N/A
12/31/2019	222,323	25,666	N/A	N/A	N/A
9/30/2019	216,070	25,733	N/A	N/A	N/A
6/30/2019	207,579	25,449	N/A	N/A	N/A
3/31/2019	195,636	23,647	919	16,510	N/A
12/31/2018	183,834	23,078	N/A	N/A	N/A
9/30/2018	174,246	21,906	N/A	N/A	N/A
6/30/2018	171,091	23,603	N/A	N/A	N/A
3/31/2018	164,630	24,232	N/A	19,545	N/A
12/31/2017	159,381	24,271	N/A	N/A	N/A
9/30/2017	154,903	24,107	N/A	N/A	N/A
6/30/2017	148,279	22,352	N/A	N/A	N/A
3/31/2017	149,334	23,017	N/A	32,786	N/A
12/31/2016	151,565	22,809	N/A	N/A	N/A
9/30/2016	147,559	22,466	N/A	N/A	N/A
6/30/2016	143,446	20,945	N/A	N/A	N/A
3/31/2016	138,162	20,251	N/A	14,198	N/A
12/31/2015	133,249	18,230	N/A	N/A	N/A
9/30/2015	129,956	16,724	N/A	N/A	N/A
6/30/2015	125,433	15,928	N/A	N/A	N/A
3/31/2015	121,340	15,758	N/A	12,368	N/A
12/31/2014	112,825	16,738	N/A	N/A	N/A
9/30/2014	102,756	17,069	N/A	N/A	N/A
6/30/2014	93,109	15,697	N/A	N/A	N/A
3/31/2014	81,002	11,729	N/A	6,463	N/A
12/31/2013	73,736	7,797	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: AUROPHARMA 'nin tahmini kazanç büyümesi (yıllık 13.9% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: AUROPHARMA şirketinin kazançlarının (yıllık 13.9% ) Indian pazarından (yıllık 18.1% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: AUROPHARMA şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: AUROPHARMA şirketinin gelirinin (yıllık 8.4% ) Indian pazarından (yıllık 10.5% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: AUROPHARMA şirketinin gelirinin (yıllık 8.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: AUROPHARMA 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 12.8 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/21 12:12
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Aurobindo Pharma Limited 54 Bu analistlerden 28, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Meeta Shetty	Asian Markets Securities Private Limited
Kamlesh Kotak	Asian Markets Securities Private Limited
Harith Ahamed	Avendus Spark

Aurobindo Pharma Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Price target increased by 12% to ₹1,503

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Price target increased by 7.9% to ₹1,292

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Price target increased by 7.6% to ₹1,087

Recent updates

Less than half of directors are independent

Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Second quarter 2025 earnings released: EPS: ₹14.00 (vs ₹12.83 in 2Q 2024)

Aurobindo Pharma Limited to Report Q2, 2025 Results on Nov 09, 2024

Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Aurobindo Pharma Limited Receives USFDA Approval for Cephalexin Tablets USP, 250 Mg and 500 Mg

Aurobindo Pharma Limited (NSEI:AUROPHARMA) entered into a binding agreement to acquire remaining 49% stake in Gls Pharma Limited from Suresh Pathak and his family members for approximately INR 225 million.

Eugia Steriles Private Limited Receives Its First Product Approval by the United States Food and Drug Administration

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma Limited Approves Interim Dividend for the Financial Year 2023-24

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Price target increased by 12% to ₹1,503

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Aurobindo Pharma Limited, Annual General Meeting, Aug 29, 2024

Aurobindo Pharma Limited (NSEI:AUROPHARMA) announces an Equity Buyback for 5,136,986 shares, representing 0.88% for INR 7,500 million.

Now 20% overvalued after recent price rise

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Price target increased by 7.9% to ₹1,292

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued after recent price rise

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Aurobindo Pharma Limited Announces Retirement of K. Ragunathan as Chairman of Board of Directors, Effective March 31, 2024

Aurobindo Pharma Limited Appoints N. Ravikiran as Chief Business Officer

Insider recently sold ₹2.1m worth of stock

Less than half of directors are independent

Dividend reduced to ₹1.50

Aurobindo Pharma Limited Receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Aurobindo Pharma Limited Approves the Resignation of Dr.(Mrs.) Avnit Bimal Singh as an Independent Director

Price target increased by 7.6% to ₹1,087

Price target increased by 7.5% to ₹1,085

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Price target increased by 7.2% to ₹1,071

Insider recently sold ₹9.7m worth of stock

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Insider recently sold ₹1.6m worth of stock

New minor risk - Insider selling

Price target increased by 10% to ₹956

Upcoming dividend of ₹3.00 per share at 0.3% yield

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before December 4, 2023

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Associate President of RAD- II recently sold ₹1.6m worth of stock

Aurobindo Pharma Limited Announces Interim Dividend for the Financial Year 2022-23

Price target increased by 8.2% to ₹721

Aurobindo Pharma Limited Announces Resignation of M. Sivakumaran as Whole-Time Director and Director

Full year 2023 earnings: EPS misses analyst expectations

Aurobindo Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

Aurobindo Pharma Limited Receives USFDA Approval for Saxagliptin Tablets, 2.5 Mg and 5 Mg

Aurobindo Pharma Limited, Annual General Meeting, Aug 25, 2023

Aurobindo Pharma Limited Announces Completion of US Fda Inspection At Unit III At Bachupally Village, Medchal Malkajgiri District, Telangana

Aurobindo Pharma Limited Announces Classification of US FDA Inspection At Unit XIV, Anakapalli District, Andhra Pradesh

Price target increased by 9.0% to ₹643

Full year 2023 earnings: EPS misses analyst expectations

Insider recently sold ₹1.3m worth of stock

Insider recently bought ₹3.2m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Aurobindo Pharma Limited Approves First Interim Dividend, Payable on or Before March 3, 2023

Aurobindo Pharma Limited Announces Completion Of US FDA Inspection At Unit IX - Reg

Consensus EPS estimates fall by 15%

Price target decreased to ₹621

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Insider recently sold ₹11m worth of stock

Insider recently sold ₹2.7m worth of stock